Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.
Allergy Therapeutics is a West Sussex, England-based commercial biotechnology company. Shares in the firm were up 11% to 1.66 pence each in London on Tuesday around noon.
The G306 Phase III trial investigated Grass MATA MPL, which is Allergy Therapeutics’ short-course subcutaneous allergen-specific immunotherapy candidate, designed to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
The trial met its primary endpoint, demonstrating statistically significant superiority of Grass MATA MPL compared to placebo during peak pollen season.
Subsequently, the study was stopped for success. Top-line analysis is expected to be made available in mid-December, and will include treatment effect data and secondary endpoint analysis.
The trial was conducted in the US and Europe at 89 sites.
‘The completion of the G306 study is an important milestone in our efforts to register this innovative treatment for the benefit of the millions of patients affected by grass allergies,’ said Chief Executive Officer Manuel Lobet.
‘This result builds upon the statistical significance also seen in the earlier G3091 field study and, subject to full top line analysis, we look forward to commencing discussions with relevant regulatory authorities to continue our journey to bring this important product to market.’
Copyright 2023 Alliance News Ltd. All Rights Reserved.
